We first compared the significant miRNAs identified in the comparison of cells derived from myeloid progenitors (CD15+, CD14+) versus cells derived from lymphoid progenitors (CD3+, CD19+, CD56+) of lung cancer patients and controls. This evidence concerns the gene CD19 and lung cancer.